UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013616
Receipt number R000015504
Scientific Title Effect of mono or dual broncholdilator therapy on daily step count and six minutes walking distance in COPD patients.
Date of disclosure of the study information 2014/05/07
Last modified on 2019/03/14 18:24:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of mono or dual broncholdilator therapy on daily step count and six minutes walking distance in COPD patients.

Acronym

Matsusaka Municipal Hospital COPD study

Scientific Title

Effect of mono or dual broncholdilator therapy on daily step count and six minutes walking distance in COPD patients.

Scientific Title:Acronym

Matsusaka Municipal Hospital COPD study

Region

Japan


Condition

Condition

COPD

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The effect of long acting B2-agonist and long-acting muscarinic antagonist on physical activity in COPD patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Average number of steps/day

Key secondary outcomes

Spirometry
Quality of life
6-min walking distance test


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Single-arm trial(35 patients)
Interventions will include 1)no-therapy for 3-to-4 weeks, 2)therapy with long-acting muscarinic antagonist alone for 3-to-4 weeks and 3)therapy with a combination of long-acting B2-agonist and long-acting muscarinic antagonist for 3-to-4 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

COPD patients that fulfil the GOLD criteria and patients that agree to provide informed consent will be included.

Key exclusion criteria

1.Patients with other serious clinical morbidities or complications will be excluded.
2.Patients with bronchial asthma
3.History of hypersensitivity to indacaterol and glycopyrronium
4.Patients during acute exacerabation
5.Patients who are judged improper to the test by an examination responsibility doctor's judgement

Target sample size

35


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Osamu Hataji

Organization

Matsusaka Municipal Hospital

Division name

Respiratory center

Zip code


Address

1550 Tonomachi,Matsusaka,Mie

TEL

0598-23-1515

Email

mch1031@city-hosp.matsusaka.mie.jp


Public contact

Name of contact person

1st name
Middle name
Last name Osamu Hataji

Organization

Matsusaka Municipal Hospital

Division name

Respiratory center

Zip code


Address

1550 Tonomachi,Matsusaka,Mie

TEL

0598-23-1515

Homepage URL


Email

mch1031@city-hosp.matsusaka.mie.jp


Sponsor or person

Institute

Matsusaka Municipal Hospital Respiratory center

Institute

Department

Personal name



Funding Source

Organization

Matsusaka Municipal Hospital

Organization

Division

Category of Funding Organization

Local Government

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Department of Pulmonary and Critical Care Medicine,Mie University Craduate School of Medicine
Department of Immunology,Mie University Graduate School of Medicine

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

松阪市民病院 呼吸器センター


Other administrative information

Date of disclosure of the study information

2014 Year 05 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2014 Year 04 Month 01 Day

Date of IRB

2014 Year 04 Month 07 Day

Anticipated trial start date

2014 Year 04 Month 07 Day

Last follow-up date

2014 Year 12 Month 27 Day

Date of closure to data entry

2015 Year 03 Month 31 Day

Date trial data considered complete

2015 Year 03 Month 31 Day

Date analysis concluded

2015 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2014 Year 04 Month 03 Day

Last modified on

2019 Year 03 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015504


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name